Advancements in the Management of R/R AML: ASH 2024 - Episode 10

Emerging Combination Strategies and Preclinical Findings

February 5, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss the interim phase 1a results from KOMET-007 in newly diagnosed NPM1-mutated or KMT2A-rearranged AML, the potential role of ziftomenib combined with 7 plus 3 chemotherapy in standard induction therapy for high-risk acute monocytic leukemia (AML) patients with these mutations, preclinical findings on the combination of ziftomenib and selinexor in NPM1-mutant AML, and the mechanistic synergy between these therapies, exploring their potential in clinical practice and across other AML subtypes.

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

Now Viewing

EP. 10: Emerging Combination Strategies and Preclinical Findings

Video content above is prompted by the following:

Dr. LeBlanc to ask Dr. Thirman: Briefly comment on the presented interim phase 1a results from KOMET-007, in newly diagnosed NPM1-mutated or KMT2A-rearranged AML. (Zeidan, AM, et al. ASH 2024. Oral Abstract 214, Session: 616or pg. 15)

Dr. LeBlanc to ask Dr. Thirman: How does the high efficacy and manageable safety profile of ziftomenib combined with 7 plus +3 chemotherapy impact its potential role in standard induction therapy for newly diagnosed high-risk AML, particularly for patients with NPM1-mutated and KMT2A-rearranged mutations?

Dr. LeBlanc to ask Dr. Mannis: Briefly comment on the preclinical findings presented regarding the combination of ziftomenib and selinexor in NPM1-mutant AML. (Dhiman, S, et al. ASH 2024. Poster Abstract 2768, Session: 604 or pg. 17)

Dr. LeBlanc to ask Dr. Mannis: How does the mechanistic synergy between ziftomenib and selinexor in NPM1-mutant AML inform potential combination strategies in clinical practice, and what are the implications for expanding this approach to other AML subtypes?